文献速递泌尿生殖技术与安全PETCT

PSMA PET/CT在预定时间点评估治疗反应对转移性去势抵抗性前列腺癌患者生存的预测优于PSA反应

PSMA PET/CT for treatment response evaluation at predefined time points is superior to PSA response for predicting survival in metastatic castration-resistant prostate cancer patients.
PubMed 文献 · Eur J Radiol · 2024-10-02

本研究回顾性分析60例mCRPC患者,在基线及治疗反应评估时点(雄激素受体靶向治疗3个月后或化疗完成后)行[18F]PSMA-1007 PET/CT,按EAU/EANM标准进行视觉评估。PSMA PET/CT与PSA反应不一致见于47%患者,PSMA PET/CT总体反应独立预测总生存(进展vs非进展HR=4.05,p<0.001),优于PSA反应(HR=2.53,p=0.010)。

要点

  • mCRPC治疗反应评估中PSMA PET/CT与PSA反应不一致率达47%,不一致者中89%为PSMA PET/CT反应更差。
  • PSMA PET/CT总体反应(进展vs非进展HR=4.05,p<0.001)独立预测总生存,优于PSA反应(HR=2.53,p=0.010)。
  • PSA下降>50%的患者中31%在PSMA PET/CT上显示进展,与更高死亡风险相关(HR=4.38,p=0.008)。

核心结论

  • 在预定时间点用PSMA PET/CT评估治疗反应,对接受雄激素受体靶向药物和化疗的mCRPC患者总生存的预测优于基于PSA的反应评估;PSMA PET/CT能比PSA更早检测疾病进展,可能影响治疗决策并有望改善患者结局。

研究设计与样本

  • 回顾性分析60例mCRPC患者,在基线及治疗反应评估时点(雄激素受体靶向药物治疗3个月后或化疗完成后)行[18F]PSMA-1007 PET/CT;采用EAU/EANM标准进行视觉评估,将总体反应和最差反应病灶的反应分为部分缓解、疾病稳定或疾病进展;计算SUVmax、总肿瘤体积和总病灶摄取(肿瘤体积×SUVmean)的百分比变化;PSA反应按PCWG3标准定义;采用Cox回归分析确定总生存预测因素。

诊断标准与关键数值

  • 视觉评估采用EAU/EANM标准,将总体反应及最差反应病灶的反应分为部分缓解、疾病稳定或疾病进展;PSA反应按PCWG3标准定义;PSMA PET/CT与PSA反应不一致见于47%患者,其中89%病例PSMA PET/CT反应更差;PSMA PET/CT总体反应独立预测总生存(进展vs非进展HR=4.05,p<0.001),优于PSA反应(进展vs非进展HR=2.53,p=0.010);PSA下降>50%的患者中31%在PSMA PET/CT上显示疾病进展,与更高死亡风险相关(进展vs非进展HR=4.38,p=0.008);本队列未观察到PSMA摄取flare。

临床应用与阅片要点

  • 作者建议进一步研究在更大患者队列中验证这些发现、扩展治疗数量并评估成本效益及对患者结局的影响;原文未据此给出其他临床推荐。

局限性

  • 原文未报告局限性;作者在结论中建议进一步研究以在更大患者队列中验证这些发现。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND: In metastatic castration-resistant prostate cancer (mCRPC), using serum prostate-specific antigen (PSA) levels to evaluate treatment response is not always accurate. This study aimed to assess the efficacy of PSMA PET/CT at specific time points for evaluating treatment response and predicting survival in mCRPC patients, compared to PSA.

METHODS: Sixty mCRPC patients underwent [18F]PSMA-1007 PET/CT at baseline and for treatment response evaluation of either androgen receptor-targeted agents (after 3 months) or chemotherapy (after completion), and were retrospectively analysed. Visual assessment categorised overall response and response of the worst responding lesion as partial response, stable disease, or progressive disease, using the EAU/EANM criteria. Additionally, percentage changes in SUVmax, total tumour volume and total lesion uptake (tumour volume * SUVmean) were calculated. PSA response was defined according to the PCWG3 criteria. Cox regression analysis identified predictors of overall survival.

RESULTS: PSMA PET/CT and PSA response were discordant in 47 % of patients, and PSMA PET/CT response was worse in 89 % of these cases. Overall response on PSMA PET/CT independently predicted overall survival (progression versus non-progression: HR = 4.05, p < 0.001), outperforming PSA response (progression versus non-progression: HR = 2.53, p = 0.010) and other PSMA PET/CT parameters. Among patients with a PSA decline of > 50 %, 31 % showed progressive disease on PSMA PET/CT, correlating with higher mortality risk (progression versus non-progression: HR = 4.38, p = 0.008). No flare in PSMA uptake was observed in this cohort.

CONCLUSIONS: PSMA PET/CT for assessing treatment response at predefined time points was superior to PSA-based response for predicting overall survival in mCRPC patients treated with androgen receptor-targeted agents and chemotherapy. PSMA PET/CT showed the ability to detect disease progression earlier than PSA levels, which can affect treatment decisions and has the potential to improve patient outcomes. We recommend further research to validate these findings in larger patient cohorts, to extend the number of treatments, and to evaluate cost-effectiveness and impact on patient outcomes.

来源:Eur J Radiol,查看原文。版权归原作者所有。

引用

  1. Kleiburg F, de Geus-Oei LF, Luelmo SAC, et al. PSMA PET/CT for treatment response evaluation at predefined time points is superior to PSA response for predicting survival in metastatic castration-resistant prostate cancer patients. Eur J Radiol. 2024. PMID: 39442347. doi:10.1016/j.ejrad.2024.111774

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。